White Plains, NY – According to filings with the U.S. Securities and Exchange Commission, Oligomerix is raising $3,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Moe played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Oligomerix
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimers disease. With a focus on oral, small molecule, tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimers disease and other dementias that are easy to administer and cost effective, and which are expected to significantly add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that was recently approved by the U.S. FDA. Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.

To learn more about Oligomerix, visit http://www.oligomerix.com/

Contact:
James Moe, Chief Executive Officer
212-568-0365
jmoe@oligomerix.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved